Home› Situations› DIM.PA — Structural weakness emerging
Situation · 2026-04-24

DIM.PA — Structural weakness emerging

Discounted for Declining Quality, Not Missed Potential

Updated 2026-04-23 · Ref: Healthcare
Key metrics — 2026-04-23
Peer score
22
Quality pct
25
Valuation pct
18
52w drawdown
-28.9%
21d vs sector
-13.6%
Peer group
Healthcare
Situation summary

Sartorius Stedim Biotech trades at a discount for declining margins and capital returns. The market sees a quality name that has lost its edge. A 31.2% EBITDA margin and 7.8% ROIC are not enough. No turnaround, no rerating.

Published by AssetNext · 2026-04-24

All companies with this signal today

View full list: Structural weakness emerging →

Related pages for DIM.PA
Full peer analysis for Sartorius Stedim Biotech S.A. →Similar companies to DIM.PADIM.PA peersAll DIM.PA comparisonsSTOXX 600 context
Signal history — last 30 days
Date Signal Peer score Drawdown 21d vs sector
2026-04-23 Structural weakness emerging 22 -28.9% -13.6%

See DIM.PA's full peer analysis

Break down DIM.PA's structural position across all peer dimensions with the interactive app.

Open DIM.PA in AssetNext →